These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22204769)

  • 1. Vaccine adjuvant properties of probiotic bacteria.
    Licciardi PV; Tang ML
    Discov Med; 2011 Dec; 12(67):525-33. PubMed ID: 22204769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune modulatory capacity of probiotic lactic acid bacteria and applications in vaccine development.
    Mojgani N; Shahali Y; Dadar M
    Benef Microbes; 2020 May; 11(3):213-226. PubMed ID: 32216470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of pneumococcal disease through vaccination.
    Gentile A; Bazán V
    Vaccine; 2011 Sep; 29 Suppl 3():C15-25. PubMed ID: 21896348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights in mucosal vaccine development.
    Pavot V; Rochereau N; Genin C; Verrier B; Paul S
    Vaccine; 2012 Jan; 30(2):142-54. PubMed ID: 22085556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-dose measles vaccination schedules.
    Rosenthal SR; Clements CJ
    Bull World Health Organ; 1993; 71(3-4):421-8. PubMed ID: 8324862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies using DNA for the induction of mucosal immunity.
    McCluskie MJ; Davis HL
    Crit Rev Immunol; 1999; 19(4):303-29. PubMed ID: 10530431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature.
    Mrsny RJ
    J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.
    Gupta RK; Chang AC; Siber GR
    Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB; Zhou H; Ponce A; Chen W
    Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines.
    Widdowson MA; Steele D; Vojdani J; Wecker J; Parashar U
    J Infect Dis; 2009 Nov; 200 Suppl 1():S1-8. PubMed ID: 19817589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global routine vaccination coverage, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Oct; 59(42):1367-71. PubMed ID: 21030941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.